1HYMES K B. Choices in the treatment of cutaneous T - cell lymphoma [ J ]. Oncology( Williston Park ) ,2007,21 ( 2 ) : 18 - 23.
2KNOBLER E. Current management strategies for cutaneous T - cell lymphoma [ J ]. Clin Dermatol,2004,22 ( 3 ) : 197 - 208.
3MCGINNIS K S,CRAWFORD G. Low - dose oral bexarotene in eom - bination with low - dose. interferon alfa in the treatment of cutaneous T - cell lymphoma clinical synergism and possible immunologic mechanisms [J]. J Am Acad Dennatol,2004,50(5) :375 - 379.
4DUMMER R, COZZIO A, MEIER S, et al. Standard and experimental therapy in cutaneous T - cell lymphomas[ J ]. Cutan Patho1,2006,1 (3) : 52 - 57.
5TSIMBERIDOU A M, GILES F, ROMAGUERA J, et al. Activity of interferon - alpha and isotretionoin in patients with advanced, refractor lymphoid malignancies [ J ]. Cancer, 2004,100 ( 4 ) : 574 - 580.
6BORCHMANN P,SCHNELL R,ENGERT A. Immunotherapy of Hodgkins lymphoma[J]. Haemstol Suppl,2005,5(66) :159 - 165.
7DUVIC M. Bexarolene and DAB389 - IL - 2 ( denileukin diflitox, ONTAK)in treatment of cutaneous T - cell lymphomas algorithms [ J ]. Clin Lymphoma ,2000,13 ( 2 ) : 51 - 57.
8PASTAN I,HASSAN R,FITZGERALD D J,et al. Immunotoxin therapy of cancer[J]. Nat Rev Cancer,2006,6(7) :559 - 565.
9ATRIA P, POWELL D J, MAKER A V, et al. Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB - 2 [ J ]. Immunother, 2006,29 ( 2 ) :208 - 214.
10HAFFNER A C, TASSIS A, ZEPTER K, et al. Expression of cancer/testis antigens in cutaneous T cell lymphomas[ J ]. Cancer,2002,97(3) : 668 - 670.
